CF
VKTX icon

Corebridge Financial’s Viking Therapeutics VKTX Stock Holding History

Corebridge Financial’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,887
Closed -$45.6K – 2709
2025
Q1 		$45.6K Sell
1,887
-73
-4% -$2.31K ﹤0.01% 2755
2024
Q4 		$78.9K Sell
1,960
-59
-3% -$3.36K ﹤0.01% 2664
2024
Q3 		$128K Sell
2,019
-73
-3% -$4.28K ﹤0.01% 2470
2024
Q2 		$111K Buy
+2,092
New +$137K ﹤0.01% 2537

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Corebridge Financial's VKTX Position: Q2 2025 in Review

Corebridge Financial sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 1,887 shares — an estimated $45.6K sold.

Corebridge Financial first reported a position in VKTX in Q2 2024 and held it in 4 quarters. The position peaked at $128K in Q3 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • Corebridge Financial reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 1,887 Viking Therapeutics shares in Q2 2025, an estimated $45.6K.
  • Corebridge Financial first reported a position in Viking Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Viking Therapeutics position peaked at $128K in Q3 2024.
  • 391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.